Trials / Completed
CompletedNCT00537329
Anidulafungin In Treatment Of Candidemia In Asian Subjects
A Phase IIIB Pilot Study Of Efficacy And Safety Of Anidulafungin In The Treatment Of Candidemia In Asian Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether or not the Investigational Study Drug anidulafungin is safe and effective in the treatment of a fungal infection, candidemia, in Asian subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anidulafungin | Eligible subjects will be initiated on a single loading dose of 200 mg IV anidulafungin, followed by 100 mg IV anidulafungin once daily for a minimum of 5 days but not more than 42 days. |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2009-03-01
- Completion
- 2009-03-01
- First posted
- 2007-10-01
- Last updated
- 2010-03-09
- Results posted
- 2010-02-17
Locations
13 sites across 4 countries: India, Philippines, Taiwan, Thailand
Source: ClinicalTrials.gov record NCT00537329. Inclusion in this directory is not an endorsement.